Literature DB >> 2835976

Psychotropic effects of repeated doses of enalapril, propranolol and atenolol in normal subjects.

G Frcka1, M Lader.   

Abstract

1 Enalapril 20 mg, propranolol 160 mg, atenolol 50 mg and placebo each were given once a day for 8 days to 12 normal volunteers, using a Latin-square design and double-blind procedures. A battery of tests was applied before, 2 and 4 h after the dose on day 1 and 8. 2 EEG effects were detected on day 8 with propranolol but not consistently after atenolol or enalapril. 3 Reaction-time, symbol copying and memory were impaired with propranolol; only memory was marginally affected by atenolol. Enalapril impaired memory but improved tapping ability. 4 Subjectively, propranolol was associated with drowsiness, enalapril with calmness and perhaps contentedness. Ratings of headache were increased with enalapril. 5 It is concluded that the apparent beneficial subjective effects of enalapril in clinical practice are attributable partly to intrinsic central effects but mainly to the contrast with beta-adrenoceptor blockers such as propranolol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835976      PMCID: PMC1386616          DOI: 10.1111/j.1365-2125.1988.tb03283.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

2.  Comparison of enalapril and bendrofluazide for treatment of systemic hypertension.

Authors:  A V Zezulka; J S Gill; I Dews; M D Joy; D G Beevers
Journal:  Am J Cardiol       Date:  1987-03-01       Impact factor: 2.778

3.  Effects of atenolol and propranolol on human performance and subjective feelings.

Authors:  A A Landauer; D A Pocock; F W Prott
Journal:  Psychopharmacology (Berl)       Date:  1979-01-31       Impact factor: 4.530

4.  Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.

Authors:  M M Ghoneim; J V Hinrichs; R Noyes; D J Anderson
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

5.  Metipranolol and propranolol: no CNS effects of a single oral dose.

Authors:  S Levander; A Gillner
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Central effects of single oral doses of propranolol in man.

Authors:  S A Salem; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Central effects of beta-adrenoceptor antagonists.

Authors:  S A Salem; D G McDevitt
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

9.  Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril.

Authors:  S G Chrysant; R D Brown; D C Kem; J L Brown
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

10.  Central and peripheral effects of propranolol and sotalol in normal human subjects.

Authors:  M H Lader; P J Tyrer
Journal:  Br J Pharmacol       Date:  1972-07       Impact factor: 8.739

View more
  9 in total

Review 1.  Noradrenergic modulation of working memory and emotional memory in humans.

Authors:  Samuel R Chamberlain; Ulrich Müller; Andrew D Blackwell; Trevor W Robbins; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-04-27       Impact factor: 4.530

2.  The effects of anti-hypertensive medication on learning and memory.

Authors:  J Powell; A Pickering; M Wyke; T Goggin
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

3.  Nootropic effects of ACE inhibitors in mice.

Authors:  C Mondadori; P Etienne
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway.

Authors:  A N Nicholson; N A Wright; M B Zetlein; D Currie; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

6.  The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

Authors:  I J Deary; S Capewell; C Hajducka; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 7.  Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.

Authors:  A M Domeney
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 8.  Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps.

Authors:  Raymond T Bartus; Reginald L Dean
Journal:  Psychopharmacology (Berl)       Date:  2008-11-15       Impact factor: 4.530

9.  Noradrenaline modulates neuronal and perceptual visual detectability via β-adrenergic receptor.

Authors:  Keisuke Tsunoda; Akinori Y Sato; Ryo Mizuyama; Satoshi Shimegi
Journal:  Psychopharmacology (Berl)       Date:  2021-09-21       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.